PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.77%
Revenue growth at 50-75% of META's 19.43%. Martin Whitman would worry about competitiveness or product relevance.
9.26%
Gross profit growth under 50% of META's 21.34%. Michael Burry would be concerned about a severe competitive disadvantage.
0.97%
EBIT growth below 50% of META's 23.28%. Michael Burry would suspect deeper competitive or cost structure issues.
0.97%
Operating income growth under 50% of META's 23.28%. Michael Burry would be concerned about deeper cost or sales issues.
50.98%
Net income growth above 1.5x META's 20.65%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
50.98%
EPS growth above 1.5x META's 21.13%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
50.98%
Diluted EPS growth above 1.5x META's 20.75%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.60%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.43%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-6.72%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-4.11%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
535.93%
10Y revenue/share CAGR under 50% of META's 1498.35%. Michael Burry would suspect a lasting competitive disadvantage.
150.87%
5Y revenue/share CAGR under 50% of META's 434.39%. Michael Burry would suspect a significant competitive gap or product weakness.
77.06%
3Y revenue/share CAGR at 50-75% of META's 144.87%. Martin Whitman would question if the firm lags behind competitor innovations.
386.50%
10Y OCF/share CAGR under 50% of META's 1427.15%. Michael Burry would worry about a persistent underperformance in cash creation.
123.45%
Below 50% of META's 460.10%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
53.51%
3Y OCF/share CAGR at 50-75% of META's 88.51%. Martin Whitman would suspect weaker recent execution or product competitiveness.
397.91%
Below 50% of META's 1986.63%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
121.11%
Below 50% of META's 930.72%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
100.41%
3Y net income/share CAGR similar to META's 111.22%. Walter Schloss would attribute it to shared growth factors or demand patterns.
415.36%
Below 50% of META's 1668.76%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
90.01%
5Y equity/share CAGR at 50-75% of META's 173.28%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
45.12%
3Y equity/share CAGR at 50-75% of META's 74.67%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.41%
AR growth well above META's 24.05%. Michael Burry fears inflated revenue or higher default risk in the near future.
-28.69%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.89%
Asset growth at 50-75% of META's 7.20%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.94%
50-75% of META's 7.84%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
7.42%
Debt growth far above META's 13.05%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
10.19%
R&D growth drastically higher vs. META's 9.27%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
18.99%
SG&A growth well above META's 28.99%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.